On January 25, 2023 Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDCs") and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, reported that its Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study II") (Interim) data has been accepted by the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) ("ASCO") Genito Urinary ("GU") Cancer Symposium for a moderated poster presentation (Press release, Theralase, JAN 25, 2023, View Source [SID1234627401]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The GU-ASCO cancer symposium will take placebetweenFebruary 16th to 18th, 2023 in San Francisco, California with the poster presented for general viewing and discussion within Poster Session B: Prostate Cancer and Urothelial Carcinoma on February 17, 2023 at 12:30 PM to 2:00 PM and 5:15 PM to 6:15 PM.

The poster titled: "A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive NMIBC (interim analysis)"will be presented by the lead author, Girish Kulkarni M.D., Ph.D., FRCSC, Divisions of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, Professor, University of Toronto, (Toronto, Ontario, Canada).

The poster will include interim clinical data and analysis collected through the enrollment and treatment of patients at all Canadian and US clinical study site by their respective principal investigators for Study II.

Arkady Mandel MD, Ph.D., D.Sc., Interim Chief Executive Officer and Chief Scientific Officer, Theralase stated, "I am delighted that Theralase will have the opportunity to showcase its latest reported interim clinical data and analysis for Study II at the coveted ASCO (Free ASCO Whitepaper) GU Cancer Symposium to leading uro-oncologists from around the world."

About ASCO (Free ASCO Whitepaper)

Founded in 1964, the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) is the world’s leading professional organization for physicians and oncology professionals caring for people with cancer.

About Study II

Study II utilizes the therapeutic dose of TLD-1433 (0.70 mg/cm2) activated by the proprietary TLC-3200 medical laser system. Study II is focused on enrolling and treating approximately 100 to 125 BCG-Unresponsive NMIBC Carcinoma In-Situ ("CIS") patients in up to 20 clinical study sites located in Canada and the United States.

About TLD-1433

TLD-1433 is a patented PDC with 12 years of published peer reviewed preclinical research and is currently under investigation in Study II.

On January 25, 2023 Nascent Biotech, Inc. (OTCQB: NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies that target various cancer types, reported the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer (Filing, 8-K, Nascent Biotech, JAN 25, 2023, View Source [SID1234626586]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab.

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells.

On January 25, 2023 AnPac Bio-Medical Science Co., Ltd. (the "Company") (Nasdaq: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and a business-to-business food e-commerce company, reported that in December 2022 and January 2023, the Company signed definitive investment agreements with several third party investors (Press release, Anpac Bio, JAN 25, 2023, View Source [SID1234626626]). The investors agreed to purchase 29,714,279 newly issued Class A ordinary shares (1,485,714 American Depositary Shares or "ADSs") of the Company at a price of US$0.175 per ordinary share or US$3.50 per ADS (1:20 ADS-to-share ratio), for a total purchase price of US$5.2 million. The closing is expected to take place within 30 days after signing. Concurrently, for each Class A ordinary share purchased, the investors will receive two warrants with each warrant to purchase one Class A ordinary share at an exercise price of US$0.21 per ordinary share (2,971,428 ADS an at exercise price of US$4.20 per ADS). The warrants will be exercisable within 2 years from the date of issuance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company expects to use the proceeds for its business-to-business Asian food e-commerce and Asian food supply chain construction.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company.

On January 25, 2023 Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) reported that the Company has entered into a strategic collaboration and licence agreement with Janssen Biotech, Inc. ("Janssen"), one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Press release, Evotec, JAN 25, 2023, View Source [SID1234626582]). The collaboration focuses on the development of first-in-class targeted immune-based therapies for oncology, which will ultimately be commercialised by Janssen. The agreement was facilitated by Johnson & Johnson Innovation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration leverages Evotec’s integrated discovery and development capabilities and manufacturing optimisation processes, including an option for the GMP manufacture of the immune-based therapies. Evotec will collaborate closely with Janssen during the pre-clinical R&D phase while Janssen will assume full responsibility for the clinical development and commercialisation.

Besides research funding, Evotec is entitled to an undisclosed upfront payment, success-based research and commercial milestones exceeding US$ 350 m as well as tiered royalties on products resulting from the collaboration.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "We are very excited about this collaboration with Janssen. Novel immune-based therapies with disease-relevant, targeted mechanisms are expected to benefit large number of patients. Evotec is committed to leading the way in transformational innovation to treat and ultimately cure diseases of high unmet need."

On January 25, 2023 Iaso Therapeutics, a Michigan State University startup developing novel technologies for next-generation vaccines, reported that it recently closed the first tranche of the company’s $1.25M Series Seed Preferred round of financing (Press release, Iaso Therapeutics, JAN 25, 2023, View Source [SID1234626559]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Proceeds from the funding will be used to advance Iaso’s customizable drug delivery and vaccine platform based on bacteriophage mQβ to boost immune system responses against weakly immunogenic antigens.

Participating in the round was the Michigan Rise Pre-Seed III Fund, Red Cedar Ventures Pre-Seed Fund and Michigan-based angel investors. Iaso Therapeutics is also eligible to receive up to $125K in funding from the Michigan Small Business Development Center and Michigan Economic Development Corporation’s Emerging Technology Fund, leveraging a successful National Science Found Phase II SBIR grant in March 2022.

"Iaso Therapeutics has successfully supported the early development of our mQβ vaccine platform with NSF and NIH SBIR grants," said Robert Forgey, President and CEO of Iaso Therapeutics. "This funding will accelerate the development of this technology as we begin our journey."

Based in East Lansing, Michigan, Iaso Therapeutics was founded in 2018 by Dr. Xuefei Huang, Ph.D., utilizing carbohydrate-based vaccine chemistry technology research in partnership with Michigan State University. Iaso Therapeutics hired Forgey as the president and CEO who brings two decades of biotechnology start-up experience.

"It has been rewarding to follow the progress of the Iaso Therapeutics since its early inception at Michigan State University," said Jeff Wesley, Executive Director of Michigan Rise Pre-Seed III. "The company is developing a platform with the potential to create vaccines for both infectious diseases and cancers, but also with the potential to deliver therapeutics to target tissues. In addition, the company, over a short period of time, has amassed strong pre-clinical animal data and can point to initial success in getting vaccines to the clinic as proof of concept."

The mQβ carrier has been conjugated with various molecules, such as small molecules, sugars, peptides, proteins, polysaccharides and glycoproteins. Thus has the potential to be a widely used carrier for both human and animal vaccines.

"Iaso Therapeutics’ technology has substantial potential to be a new safe and highly efficient vaccine platform," said Don Parfet, Managing Director of the Apjohn Group LLC and Iaso Therapeutics investor. "I really like the team and am impressed by the progress that has been made under the support and oversight of Spartan Innovations and MSU Technologies."

The overall increase in infectious and noninfectious diseases, growing population and recent technological advancements in vaccines and enabling technologies create considerable scope for the overall vaccine market. The resurgence of vaccine preventable diseases and the emergence of new pandemics and immunization programs in emerging economies also heavily influence the global vaccine market.

Iaso Therapeutics expects to complete this Series Seed Preferred round of financing later this year.